Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Virology|August 28, 2012
In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteinsGhada Khawaja, Thierry Buronfosse, Catherine Jamard, et al.
Vaccine|March 4, 2021
Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccinesMargaret Stanley, Elmar Joura, Glorian P Yen, et al.
Vaccine|November 26, 2020
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging studyZhuhang Huang, Jianfeng He, Jiali Su, et al.
Pediatrics|July 9, 2024
Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV VaccineNicola P Klein, Amy Wiesner, Oliver Bautista, et al.
Vaccine|September 29, 2015
Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccineSuzanne M Garland, Tak-Hong Cheung, Shelly McNeill, et al.
Msphere|March 17, 2023
Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine TypesKatrina M Nolan, Brent Seaton, Joseph Antonello, et al.
Tumour Virus Research|May 7, 2022
Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young womenDarron R Brown, Xavier Castellsagué, Daron Ferris, et al.
Vaccine|March 21, 2021
Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidenceDarron R Brown, Elmar A Joura, Glorian P Yen, et al.
The Journal of Infectious Diseases|December 16, 2025
Assessment of Concordant Human Papillomavirus Infection With 9-Valent Vaccine Types Across Anogenital Sites in Young MenCara J Broshkevitch, Anna R Giuliano, Joel M Palefsky, et al.
Vaccine|April 29, 2022
Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label studyHuakun Lv, Shenyu Wang, Zhenzhen Liang, et al.
Pageof 7